Key stats
About ALNYLAM PHARDRN
Sector
CEO
Yvonne L. Greenstreet
Headquarters
Cambridge
Website
Founded
2002
ISIN
BRA1LNBDR003
FIGI
BBG00XV4BP79
Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where A1LN34 is featured.